EMERGENT-5: Cobenfy and Treatment Durability

Psychopharmacology and Psychiatry Updates by Psychopharmacology Institute

Sep 18, 202612:55Health

In this episode, we sit down with Dr. Oliver Freudenreich to unpack EMERGENT-5, the year-long trial tracking Cobenfy's real-world durability and safety in schizophrenia. We explore whether early symptom gains hold up ove...

Related Episodes

Continue listening to more episodes from Psychopharmacology and Psychiatry Updates.

SSRI Dosing for OCD: Beyond FDA Guidelines

Oct 3, 2026 - 09:10

Faculty: Robert Hudak, M.D. Host: Flavio Guzmán, M.D. Learn more about our memberships here Earn 1.25 CME...

Trazodone for Insomnia and Comorbid Depression

Sep 28, 2026 - 10:57

In this episode, we explore a new meta-analysis reconciling trazodone's real-world reputation with cautio...

Antipsychotics, Prolactin, and Sexual Side Effects

Sep 23, 2026 - 08:48

In this episode, we explore why antipsychotics cause hyperprolactinemia and sexual side effects, a leadin...

Antipsychotics and Weight Gain

Sep 13, 2026 - 14:59

In this episode, we sit down with Dr. Oliver Freudenreich to unpack antipsychotic-induced weight gain — w...

EPA vs. DHA: Fish Oil and Treatment-Resistant Depression

Sep 8, 2026 - 12:41

In this episode, we explore whether EPA, a specific omega-3 fatty acid, can help patients with treatment-...

AUD Medications and Hepatic Safety

Sep 3, 2026 - 10:14

In this episode, we explore how liver status shapes medication choice for alcohol use disorder. Dr. Kevin...

GLP-1 Agonists in Serious Mental Illness: Current Evidence

Aug 29, 2026 - 15:27

In this episode, we explore whether GLP-1 agonists like semaglutide can tackle the metabolic toll of anti...

Gabapentin, Topiramate & Baclofen in AUD

Aug 24, 2026 - 17:22

In this episode, we explore three off-label but evidence-supported medications — gabapentin, topiramate,...